| Molecule | Cat. No. | Product Name | 種 | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| HLA-A*0201 & B2M & MAGE-A4 (KVLEHVVRV) | Biotinylated Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | |||
| HLA-A*0201 & B2M & MAGE-A4 (KVLEHVVRV) | PE-Labeled Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Tetramer Protein | Human | HEK293 | $410.00 25ug |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Ecopipam | PSYRX-101; Sch-39166 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Language Disorders; Speech Disorders; Self-Injurious Behavior; Lesch-Nyhan Syndrome; Childhood-Onset Fluency Disorder; Tourette Syndrome; Gambling; Stuttering | 詳細 |
| Tavapadon | CVL-751; PF-6649751; PF-06649751 | Phase 3 Clinical | Pfizer Inc, Cerevel Therapeutics Llc | Kidney Diseases; Parkinson Disease; Hepatic Insufficiency | 詳細 |
| Thioridazine | TP-21 | Phase 3 Clinical | Novartis Pharma Ag | Schizophrenia; Anxiety Disorders; Carcinoma, Hepatocellular | 詳細 |
| Olanzapine long acting injectable (Teva Pharmaceutical Industries) | TV-44749; TEV-‘749; mdc-TJK | Phase 3 Clinical | Medincell SA | Schizophrenia | 詳細 |
| PF-06412562 | PF-6412562; PF-06412562 | Phase 2 Clinical | Pfizer Inc | Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders; Parkinson Disease | 詳細 |
| Mevidalen | LY-3154207 | Phase 2 Clinical | Eli Lilly And Company | Parkinson Disease; Lewy Body Disease | 詳細 |
| TGOF02N | TGOF-02N; TGOF02N; FKF02SC | Phase 2 Clinical | Fabre-Kramer | Schizophrenia | 詳細 |
| ASP-4345 | ASP-4345 | Phase 2 Clinical | Astellas Pharma Inc | Schizophrenia | 詳細 |
| Docarpamine (Martin Pharmaceuticals) | Phase 2 Clinical | Martin Pharmaceuticals Inc | Gastrointestinal Diseases; Liver Cirrhosis; Mouth Diseases | 詳細 | |
| CVL-871 | CVL-871 | Phase 2 Clinical | Pfizer Inc | Dementia | 詳細 |
| [11C]NNC-112 | [11C]NNC-112 | Phase 2 Clinical | Glaxosmithkline Plc | Diagnostic agents | 詳細 |
| Lu-AF-28996 | Phase 1 Clinical | H. Lundbeck A/S | Parkinson Disease | 詳細 | |
| Olanzapine intranasal (Neurelis) | NRL-4; NRL-1004 | Phase 1 Clinical | Neurelis Inc | Bipolar Disorder | 詳細 |
| Oxytocin/Methylergometrine Maleate | Phase 1 Clinical | Nanjing Gritpharma Co Ltd | Hemorrhage; Obstetric Labor Complications | 詳細 | |
| ITI-333 | ITI-333 | Phase 1 Clinical | Intra-Cellular Therapies Inc | Mood Disorders; Pain; Opioid-Related Disorders | 詳細 |
| PF-06730110 | PF-06730110; [18F]MNI-968 | Phase 1 Clinical | Invicro Llc | Nerve Degeneration | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Docarpamine | TA-870; TA-8704 | Approved | Tanadopa | Heart Failure | null | 1994-01-01 | Heart Failure | 詳細 | ||
| Olanzapine/Fluoxetine hydrochloride | OFC | Approved | Eli Lilly And Company | Symbyax | United States | Bipolar Disorder | Eli Lilly And Company | 2003-12-24 | Depressive Disorder, Major; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Treatment-Resistant | 詳細 |
| Zuclopenthixol Hydrochloride | LU-0108 | Approved | Clopixol | Bipolar Disorder; Schizophrenia | null | 1962-01-01 | Schizophrenia; Bipolar Disorder | 詳細 | ||
| Methylergometrine Maleate | Approved | Metenarin, Methergine, Ryegonivin, Basofortina, Methylergobrevin | Postpartum Hemorrhage; Uterine Cervical Incompetence; Uterine Hemorrhage; Uterine Inertia | 詳細 | ||||||
| Samidorphan/Olanzapine | ALKS-3831 | Approved | Alkermes Plc | Lybalvi | United States | Bipolar Disorder; Schizophrenia | Alkermes Inc | 2021-05-28 | Schizophrenia; Bipolar Disorder; Psychotic Disorders; Bipolar and Related Disorders; Alcoholism | 詳細 |
| Olanzapine | LY-170053; INP-105; TEV-‘749; LY-170052; ALKS-7921 | Approved | Eli Lilly And Company | Zyprexa Relprevv, Olansek, Zyprexa Zydis, Olanzapine ODF, 再普乐, Midax, Lanzac, Zyprexa, Zypadhera, Zalasta, Zyprexa Velotab | EU | Schizophrenia; Bipolar Disorder | null | 1996-09-27 | Opioid-Related Disorders; Chemotherapy-induced nausea and vomiting; Fasting; Anorexia Nervosa; Borderline Personality Disorder; Depressive Disorder, Treatment-Resistant; Gambling; Nausea; Vomiting; Postoperative Nausea and Vomiting; Emergence Delirium; Feeding and Eating Disorders; Malaria, Falciparum; Autistic Disorder; Hematologic Neoplasms; Neoplasms; Insulin Resistance; Anorexia; Bipolar Disorder; Psychotic Disorders; Bipolar and Related Disorders; Depression; Stomach Neoplasms; Depressive Disorder, Major; Schizophrenia; Substance-Related Disorders; Weight Loss; Solid tumours | 詳細 |
| Phenylpropanolamine Hydrochloride | Approved | Nasadec, Nasathera, Pararhinol | Nasal Obstruction | 詳細 | ||||||
| Fenoldopam Mesylate | SKF-82526; SKF-82526J; (±)-SKF-82526 | Approved | Abbott Laboratories | Corlopam | United States | Hypertension | Hospira Inc | 1997-09-23 | Hypertension | 詳細 |
| Olanzapine/Hydroxyzine pamoate | Approved | Nausea | 詳細 | |||||||
| Stepholidine | Approved | Mainland China | Headache; Attention Deficit Disorder with Hyperactivity; Tourette Syndrome; Migraine Disorders | null | 1995-01-01 | Headache; Migraine Disorders; Attention Deficit Disorder with Hyperactivity; Tourette Syndrome | 詳細 |
